AffiliationCentre for Cancer Epidemiology, Christie Hospital NHS Trust, Withington, Manchester, United Kingdom.
MetadataShow full item record
AbstractThe mathematic models used to assess the benefits and cost-effectiveness of cervical screening reveal little consistency in the definition of disease status, the basic assumptions made, or the data used in the model. Conclusions derived from the models often are model and data dependent. Several authors have used simplified models and unrealistic assumptions, such as the failure to differentiate between different grades of dysplasia, or 100% sensitivity for the screening test. The Markov process assumes that the rate of transfer between states is independent of the duration of time spent in one state, and this assumption may be unsound. The difficulty with all models is in interpreting the appropriateness of the parameter values. Some are well documented, for example, stage-specific survival rates for treated patients or attendance for screening. Many, however, cannot be given a fixed value. The large number of factors that appear implicated in the incidence of and mortality from cervical cancer can lead to many feasible sets of parameter values that generate output that approaches the observed data.
CitationAssessing the effectiveness of cervical screening. 1995, 38 (3):577-84 Clin Obstet Gynecol
JournalClinical Obstetrics and Gynecology
- Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
- Authors: Hutchinson ML, Berger BM, Farber FL
- Issue date: 2000 Jul
- VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation.
- Authors: Xie Y, Tan X, Shao H, Liu Q, Tou J, Zhang Y, Luo Q, Xiang Q
- Issue date: 2017 Jan 25
- The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
- Authors: Felix JC, Lacey MJ, Miller JD, Lenhart GM, Spitzer M, Kulkarni R
- Issue date: 2016 Jun
- Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
- Authors: Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM
- Issue date: 2001 Aug
- Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
- Authors: Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E
- Issue date: 2004 Apr 21